Fox Chase Researchers Identify Possible Biomarkers in Bladder Cancer Patients Receiving Therapy Before Surgery
PHILADELPHIA (June 18, 2020)—In a recent study, researchers at Fox Chase Cancer Center found that muscle-invasive bladder cancer patients with specific gene mutations have better survival outcomes when treated with chemotherapy before surgery. The five-year survival rate for patients with at least one mutation was 85 percent, compared to 45 percent for patients without a mutation.